Edward Jensen, the new chief operating officer at US-based Blueprint Bio, has described his excitement at being part of "arguably the most groundbreaking" venture in health care.
Mr Jensen has previously worked at companies including US health care giant Johnson & Johnson (NYSE: JNJ), biotech major Biogen (Nasdaq: BIIB) and Anglo-Swedish pharma firm AstraZeneca (LSE: AZN).
He is joining the executive team of the California-based company with immediate effect, and as COO will be responsible for all strategic operations and execution.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze